Levetiracetamum Eugia

Levetiracetam, the active ingredient in Levetiracetamum Eugia, is an anticonvulsant presented as an injection solution for intravenous use. It is used as adjunctive therapy for partial‑onset, generalized tonic‑clonic and myoclonic seizures in patients with epilepsy.

GNH USA supplies Levetiracetamum Eugia as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Levetiracetam is an anticonvulsant indicated for adjunctive treatment of several seizure types.

- Partial‑onset seizures: reduces seizure frequency when added to existing antiepileptic therapy. - Generalized tonic‑clonic seizures: provides additional seizure control in patients with refractory episodes. - Myoclonic seizures: helps decrease myoclonic seizure episodes as part of combination therapy.

Levetiracetam may be associated with a range of adverse reactions, varying in frequency and severity.

Common Side Effects: - Dizziness: transient sensation of light‑headedness. - Fatigue: feeling unusually tired or weak. - Headache: mild to moderate head pain. - Irritability: increased agitation or mood changes.

Serious or Rare Side Effects: - Severe allergic reaction: rash, swelling, or anaphylaxis. - Mood or behavior changes: depression, suicidal thoughts, or aggression. - Hematologic abnormalities: low blood cell counts. - Stevens‑Johnson syndrome: severe skin blistering.

When prescribing levetiracetam, clinicians should consider several safety aspects.

- Renal function: adjust use in patients with impaired renal clearance. - Pregnancy: safety not established; use only if benefit outweighs risk. - Concomitant CNS depressants: monitor for additive sedation. - Psychiatric history: observe for mood alterations. - Discontinue gradually: avoid abrupt cessation to reduce seizure recurrence. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Levetiracetam can interact with other medicines, requiring attention to potential changes in efficacy or safety.

Major Interactions (Avoid): - Carbamazepine: may reduce levetiracetam plasma levels. - Phenobarbital: may decrease levetiracetam efficacy. - Rifampicin: may increase clearance, lowering therapeutic effect.

Moderate Interactions (Monitor Closely): - Valproic acid: may increase risk of central nervous system depression. - Sedative antihistamines: may enhance dizziness or fatigue. - Alcohol: may potentiate central nervous system effects.